biomarker development
Troubleshooting Biomarker Development Strategies
June 09 by Gabriele DallmannIn this Pharma IQ interview Kristof Vercruysse, Director Clinical Operations at Ablynx, speaks to Dr. Gabriele Dallmann, CEO of Pharmatching GmbH, about innovation in phase I clinical developme...
Improving Biomarker Development Work Flow in Phase I Clinical Development
September 07 by Helen WinsorReto Ossola, Group Leader for Biomarker Research at Biognosys, joins Pharma IQ to discuss the main challenges in biomarker development and some key ways to address these. Ossola offers some best...
Streamlining the Development and Validation Process in Discovery to Phase I Clinical Development
September 05 by Pharma IQReto Ossola, Group Leader for Biomarket Research at Biognosys, joins Helen Winsor from Pharma IQ, to discuss phase I clinical development. He outlines where he sees the main challenges in biomarker de...
Best Practice Tips for Overcoming Obstacles in Biomarker Development
July 29 by Pharma IQHow can we overcome the latest challenges in Biomarker Development? Birgitte Søgaard, Divisional Director for Clinical Pharmacology and Translational Medicine at H Lundbeck A/S, discusses wit...
How to Optimise Your Biomarker Development Strategies
April 25 by Kristof VercruysseKristof Vercruysse, Director Clinical Operations at Ablynx, speaks to Dr. Gabriele Dallmann, CEO of Pharmatching GmbH about Innovation in phase 1 clinical development and optimisation of biomarker d...
